PTC Therapeutics, Inc. Files for a $85 Million IPO Following Failed IPO Attempt in 2006
5/17/2013 7:16:44 AM
More...
|
PTC Therapeutics, Inc. Appoints Mark Rothera as Chief Commercial Officer
4/23/2013 7:33:54 AM
More...
|
PTC Therapeutics, Inc. Closes $60 Million Private Financing
3/7/2013 11:12:05 AM
More...
|
PTC Therapeutics, Inc. Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
12/6/2012 9:47:07 AM
More...
|
PTC Therapeutics, Inc. Appoints Geoffrey McDonough, M.D., To Board of Directors
11/6/2012 12:08:41 PM
More...
|
PTC Therapeutics, Inc. Receives $1 Million Grant Award From the National Institutes of Health (NIH) to Support Research for a Treatment for Dengue Fever
10/22/2012 9:44:27 AM
More...
|
PTC Therapeutics, Inc. Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors
9/28/2012 10:06:59 AM
More...
|
PTC Therapeutics, Inc. Closes $30 Million Financing
7/23/2012 6:25:42 AM
More...
|
PTC Therapeutics, Inc. Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
7/11/2012 10:16:16 AM
More...
|
PTC Therapeutics, Inc. Initiates Open-Label Study for Ataluren in Patients with Nonsense Mutation Duchenne/Becker Muscular Dystrophy
6/27/2012 10:56:15 AM
More...
|
|